Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anxiolytic antidepressant augmentation

N Sussman1

  • 1Department of Psychiatry, New York University School of Medicine, New York 10021, USA.

The Journal of Clinical Psychiatry
|June 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychosomatic medicine.

Pennsylvania medical journal (1928)·2010
Same author

Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.

Postgraduate medicine·2009
Same author

Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis.

American journal of physiology. Lung cellular and molecular physiology·2008
Same author

A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.

Journal of clinical pharmacology·2008
Same author

Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006
Same author

Background and rationale for use of anticonvulsants in psychiatry.

Cleveland Clinic journal of medicine·2002
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Buspirone enhances antidepressant response by activating serotonin receptors, unlike benzodiazepines. This anxiolytic agent shows effectiveness and safety as an augmentation therapy for depression.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Anxiolytic drugs are frequently co-administered with antidepressants.
  • Benzodiazepines can alleviate anxiety and sleep issues but do not improve antidepressant efficacy.
  • Buspirone, an anxiolytic, demonstrates potential in enhancing antidepressant treatment.

Purpose of the Study:

  • To evaluate the role of buspirone as an augmentation agent in antidepressant pharmacotherapy.
  • To investigate the mechanism by which buspirone may enhance antidepressant response.
  • To assess the safety and efficacy of buspirone in combination with antidepressants.

Main Methods:

  • Review of case studies and open-label trials.
  • Analysis of buspirone's mechanism of action involving 5-HT1A receptor activation.

Related Experiment Videos

  • Assessment of adverse effects associated with buspirone augmentation.

    • Main Results:

    • Buspirone facilitates direct antidepressant response.
    • Activation of presynaptic and postsynaptic 5-HT1A receptors modulates serotonin release.
    • Case studies and open-label trials indicate buspirone's effectiveness as an augmentation agent.

    Conclusions:

    • Buspirone is an effective and safe option for augmenting antidepressant pharmacotherapy.
    • Its mechanism involves modulating serotonin release via 5-HT1A receptor activation.
    • Buspirone offers a beneficial addition to depression treatment with minimal adverse effects.